Ryvu Therapeutics SA (RVU) — Capital Reinvestment Ratio

Latest as of December 2022: 0.07x

Ryvu Therapeutics SA (RVU) has a Capital Reinvestment Ratio of 0.07x as of December 2022, meaning it reinvests 0% of its operating cash flow (zł59.92 Million) in capital expenditures (zł4.22 Million). See RVU net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.07x
Capex / Operating Cash Flow

Operating Cash Flow

zł59.92 Million
PLN

Capital Expenditures

zł4.22 Million
PLN

Data as of

Dec 2022
Most recent filing

Ryvu Therapeutics SA Capital Reinvestment Ratio (2017–2022)

This chart tracks Ryvu Therapeutics SA's Capital Reinvestment Ratio across 2 annual periods. Check RVU cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Ryvu Therapeutics SA (2017–2022)

Year-by-year Capital Reinvestment Ratio for Ryvu Therapeutics SA from 2017 to 2022. For live market cap and broader valuation context, see Ryvu Therapeutics SA (RVU) total market value.

Year Reinvestment Ratio Operating CF (PLN) Capital Expenditures YoY Change
2022 0.44x zł21.32 Million zł9.29 Million ▼ -77.8%
2017 1.96x zł10.98 Million zł21.56 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow